These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
381 related articles for article (PubMed ID: 27230605)
21. A phase II study of biweekly paclitaxel and carboplatin in elderly patients with advanced non-small cell lung cancer. Soejima K; Naoki K; Ishioka K; Nakamura M; Nakatani M; Kawada I; Watanabe H; Nakachi I; Yasuda H; Satomi R; Nakayama S; Yoda S; Ikemura S; Terai H; Sato T; Ohgino K; Arai D; Tani T; Kuroda A; Nishino M; Betsuyaku T Cancer Chemother Pharmacol; 2015 Mar; 75(3):513-9. PubMed ID: 25563719 [TBL] [Abstract][Full Text] [Related]
22. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer. Fang Y; Wang L; Xia GH; Shi MQ Asian Pac J Cancer Prev; 2014; 15(17):7453-7. PubMed ID: 25227858 [TBL] [Abstract][Full Text] [Related]
23. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. Lara PN; Douillard JY; Nakagawa K; von Pawel J; McKeage MJ; Albert I; Losonczy G; Reck M; Heo DS; Fan X; Fandi A; Scagliotti G J Clin Oncol; 2011 Aug; 29(22):2965-71. PubMed ID: 21709202 [TBL] [Abstract][Full Text] [Related]
24. Phase I/II study of carboplatin plus nab-paclitaxel and concurrent radiotherapy for patients with locally advanced non-small cell lung cancer. Kawano Y; Sasaki T; Yamaguchi H; Hirano K; Horiike A; Satouchi M; Hosokawa S; Morinaga R; Komiya K; Inoue K; Fujita Y; Toyozawa R; Kimura T; Takahashi K; Nishikawa K; Kishimoto J; Nakanishi Y; Okamoto I Lung Cancer; 2018 Nov; 125():136-141. PubMed ID: 30429011 [TBL] [Abstract][Full Text] [Related]
25. Phase I study of weekly nab-paclitaxel plus carboplatin and concurrent thoracic radiotherapy in elderly patients with unresectable locally advanced non-small cell lung cancer. Omori S; Harada H; Mori K; Hisamatsu Y; Tsuboguchi Y; Yoshioka H; Morinaga R; Daga H; Kurata T; Takahashi T Invest New Drugs; 2022 Feb; 40(1):106-114. PubMed ID: 34495421 [TBL] [Abstract][Full Text] [Related]
26. A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma. Jin F; Zhu H; Shi F; Kong L; Yu J Clin Interv Aging; 2016; 11():167-73. PubMed ID: 26929611 [TBL] [Abstract][Full Text] [Related]
27. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. Kubota K; Yoshioka H; Oshita F; Hida T; Yoh K; Hayashi H; Kato T; Kaneda H; Yamada K; Tanaka H; Ichinose Y; Park K; Cho EK; Lee KH; Lin CB; Yang JC; Hara K; Asato T; Nakagawa K J Clin Oncol; 2017 Nov; 35(32):3662-3670. PubMed ID: 28902534 [TBL] [Abstract][Full Text] [Related]
28. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. Zinner RG; Obasaju CK; Spigel DR; Weaver RW; Beck JT; Waterhouse DM; Modiano MR; Hrinczenko B; Nikolinakos PG; Liu J; Koustenis AG; Winfree KB; Melemed SA; Guba SC; Ortuzar WI; Desaiah D; Treat JA; Govindan R; Ross HJ J Thorac Oncol; 2015 Jan; 10(1):134-42. PubMed ID: 25371077 [TBL] [Abstract][Full Text] [Related]
29. A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer. Hattori Y; Kono Y; Itoh S; Inoue T; Urata Y; Kawa Y; Tohnai R; Kumagai T; Nishino K; Uozumi R; Morita S; Negoro S; Imamura F; Satouchi M BMC Cancer; 2020 Feb; 20(1):115. PubMed ID: 32046667 [TBL] [Abstract][Full Text] [Related]
30. A randomised phase II clinical trial of nab-paclitaxel and carboplatin compared with gemcitabine and carboplatin as first-line therapy in advanced squamous cell lung carcinoma (C-TONG1002). Wang Z; Huang C; Yang JJ; Song Y; Cheng Y; Chen GY; Yan HH; Ben XS; Wang BC; Xu CR; Jiang BY; Zhou Q; Chen HJ; Wu YL Eur J Cancer; 2019 Mar; 109():183-191. PubMed ID: 30739019 [TBL] [Abstract][Full Text] [Related]
31. A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancer. Okuma Y; Hosomi Y; Takahashi S; Nakahara Y; Watanabe K; Nagamata M; Takagi Y; Mikura S Cancer Chemother Pharmacol; 2016 Aug; 78(2):383-8. PubMed ID: 27339149 [TBL] [Abstract][Full Text] [Related]
32. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. Scagliotti GV; Vynnychenko I; Park K; Ichinose Y; Kubota K; Blackhall F; Pirker R; Galiulin R; Ciuleanu TE; Sydorenko O; Dediu M; Papai-Szekely Z; Banaclocha NM; McCoy S; Yao B; Hei YJ; Galimi F; Spigel DR J Clin Oncol; 2012 Aug; 30(23):2829-36. PubMed ID: 22753922 [TBL] [Abstract][Full Text] [Related]
33. nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer. Lammers PE; Lu B; Horn L; Shyr Y; Keedy V Oncologist; 2015 May; 20(5):491-2. PubMed ID: 25845992 [TBL] [Abstract][Full Text] [Related]
34. Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally Advanced and Metastatic Non-small Cell Lung Cancer. Gong W; Sun P; Mu Z; Liu J; Yu C; Liu A Anticancer Res; 2017 Aug; 37(8):4687-4691. PubMed ID: 28739772 [TBL] [Abstract][Full Text] [Related]
35. Phase 2 study of bevacizumab plus carboplatin/nab-paclitaxel followed by bevacizumab plus nab-paclitaxel for non-squamous non-small cell lung cancer with malignant pleural effusion. Tamiya M; Tamiya A; Suzuki H; Taniguchi Y; Katayama K; Minomo S; Nakao K; Takeuchi N; Matsuda Y; Naito Y; Shiroyama T; Okamoto N; Okishio K; Kumagai T; Atagi S; Imamura F; Hirashima T Invest New Drugs; 2021 Aug; 39(4):1106-1112. PubMed ID: 33544282 [TBL] [Abstract][Full Text] [Related]
36. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422 [TBL] [Abstract][Full Text] [Related]
37. Feasibility study of adjuvant chemotherapy with modified weekly nab-paclitaxel and carboplatin for completely resected non-small-cell lung cancer: FAST-nab. Saji H; Marushima H; Miyazawa T; Sakai H; Kimura H; Kurimoto N; Nakamura H Anticancer Drugs; 2017 Aug; 28(7):795-800. PubMed ID: 28538017 [TBL] [Abstract][Full Text] [Related]
38. A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol. Kogure Y; Saka H; Takiguchi Y; Atagi S; Kurata T; Ebi N; Inoue A; Kubota K; Takenoyama M; Seto T; Kada A; Yamanaka T; Ando M; Yamamoto N; Gemma A; Ichinose Y Clin Lung Cancer; 2018 Sep; 19(5):e711-e715. PubMed ID: 29861395 [TBL] [Abstract][Full Text] [Related]
39. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. Lynch TJ; Bondarenko I; Luft A; Serwatowski P; Barlesi F; Chacko R; Sebastian M; Neal J; Lu H; Cuillerot JM; Reck M J Clin Oncol; 2012 Jun; 30(17):2046-54. PubMed ID: 22547592 [TBL] [Abstract][Full Text] [Related]
40. Phase II study of nab-paclitaxel + carboplatin for patients with non-small-cell lung cancer and interstitial lung disease. Kenmotsu H; Yoh K; Mori K; Ono A; Baba T; Fujiwara Y; Yamaguchi O; Ko R; Okamoto H; Yamamoto N; Ninomiya T; Ogura T; Kato T Cancer Sci; 2019 Dec; 110(12):3738-3745. PubMed ID: 31608537 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]